Humacyte Inc. (HUMAW)
undefined
undefined%
At close: undefined
1.39
0.00%
After-hours Dec 13, 2024, 03:52 PM EST

Company Description

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.

The company was founded in 2004 and is headquartered in Durham, North Carolina.

Humacyte Inc.
Humacyte Inc. logo
Country United States
IPO Date n/a
Industry Biotechnology
Sector Healthcare
Employees 183
CEO Dr. Laura E. Niklason M.D., Ph.D.

Contact Details

Address:
No Address available
No city data available,
United States
Website n/a

Stock Details

Ticker Symbol HUMAW
Exchange NASDAQ
Fiscal Year n/a
Reporting Currency USD
CIK Code 0001818382
CUSIP Number 44486Q111
ISIN Number US44486Q1114
Employer ID 85-1763759
SIC Code 2836

Key Executives

Name Position
Dr. Laura E. Niklason M.D., Ph.D. Founder, President, Chief Executive Officer & Director
Dale A. Sander Chief Financial Officer, Chief Corporate Development Officer & Treasurer
Dr. Heather Ledbetter Prichard Ph.D. Chief Operating Officer
Sabrina Osborne GPHR, SPHR Chief People Officer
Dr. Shamik J. Parikh M.D. Chief Medical Officer
Dr. Yang Cao M.D., Ph.D. Chief Regulatory Officer
Harold Alterson Chief Quality Officer
William John Scheessele Chief Commercial Officer

Latest SEC Filings

Date Type Title
Dec 04, 2024 4 Filing
Nov 21, 2024 4 Filing
Nov 21, 2024 4 Filing
Nov 20, 2024 SC 13D/A [Amend] Filing
Nov 20, 2024 4 Filing
Nov 20, 2024 4 Filing
Nov 18, 2024 SC 13D/A [Amend] Filing
Nov 14, 2024 8-K Current Report
Nov 14, 2024 424B3 Filing
Nov 08, 2024 10-Q Quarterly Report